vs

Side-by-side financial comparison of ARROWHEAD PHARMACEUTICALS, INC. (ARWR) and KADANT INC (KAI). Click either name above to swap in a different company.

KADANT INC is the larger business by last-quarter revenue ($271.6M vs $264.0M, roughly 1.0× ARROWHEAD PHARMACEUTICALS, INC.). ARROWHEAD PHARMACEUTICALS, INC. runs the higher net margin — 11.7% vs 10.2%, a 1.5% gap on every dollar of revenue. On growth, ARROWHEAD PHARMACEUTICALS, INC. posted the faster year-over-year revenue change (10461.3% vs -0.0%). KADANT INC produced more free cash flow last quarter ($44.1M vs $11.3M).

Arrowhead Pharmaceuticals, Inc. is a publicly traded biopharmaceutical company based in Pasadena, California. Arrowhead's products in development act through RNA interference (RNAi) mechanisms of action. The company focuses on treatments for hepatitis B, liver disease associated with alpha 1-antitrypsin deficiency and cardiovascular disease.

Kadant Inc. is a company that was established in 1991, as a partly privately owned subsidiary of Thermo Electron, and partly publicly traded company, and was fully spun out and renamed Kadant in 2001. The company supports papermaking, paper recycling, wood processing, material handling, and other processing industries. Kadant is a multi-national corporation with operations in Asia, Europe, North America, and South America.

ARWR vs KAI — Head-to-Head

Bigger by revenue
KAI
KAI
1.0× larger
KAI
$271.6M
$264.0M
ARWR
Growing faster (revenue YoY)
ARWR
ARWR
+10461.3% gap
ARWR
10461.3%
-0.0%
KAI
Higher net margin
ARWR
ARWR
1.5% more per $
ARWR
11.7%
10.2%
KAI
More free cash flow
KAI
KAI
$32.7M more FCF
KAI
$44.1M
$11.3M
ARWR

Income Statement — Q1 FY2026 vs Q3 FY2025

Metric
ARWR
ARWR
KAI
KAI
Revenue
$264.0M
$271.6M
Net Profit
$30.8M
$27.7M
Gross Margin
45.2%
Operating Margin
15.5%
15.7%
Net Margin
11.7%
10.2%
Revenue YoY
10461.3%
-0.0%
Net Profit YoY
117.8%
-12.2%
EPS (diluted)
$0.22
$2.35

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
ARWR
ARWR
KAI
KAI
Q4 25
$264.0M
Q3 25
$271.6M
Q2 25
$255.3M
Q1 25
$239.2M
Q4 24
$258.0M
Q3 24
$271.6M
Q2 24
$274.8M
Q1 24
$249.0M
Net Profit
ARWR
ARWR
KAI
KAI
Q4 25
$30.8M
Q3 25
$27.7M
Q2 25
$26.2M
Q1 25
$24.1M
Q4 24
$24.0M
Q3 24
$31.6M
Q2 24
$31.3M
Q1 24
$24.7M
Gross Margin
ARWR
ARWR
KAI
KAI
Q4 25
Q3 25
45.2%
Q2 25
45.9%
Q1 25
46.1%
Q4 24
43.4%
Q3 24
44.7%
Q2 24
44.4%
Q1 24
44.6%
Operating Margin
ARWR
ARWR
KAI
KAI
Q4 25
15.5%
Q3 25
15.7%
Q2 25
15.4%
Q1 25
14.9%
Q4 24
14.3%
Q3 24
18.0%
Q2 24
17.6%
Q1 24
14.8%
Net Margin
ARWR
ARWR
KAI
KAI
Q4 25
11.7%
Q3 25
10.2%
Q2 25
10.2%
Q1 25
10.1%
Q4 24
9.3%
Q3 24
11.6%
Q2 24
11.4%
Q1 24
9.9%
EPS (diluted)
ARWR
ARWR
KAI
KAI
Q4 25
$0.22
Q3 25
$2.35
Q2 25
$2.22
Q1 25
$2.04
Q4 24
$2.04
Q3 24
$2.68
Q2 24
$2.66
Q1 24
$2.10

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
ARWR
ARWR
KAI
KAI
Cash + ST InvestmentsLiquidity on hand
$715.0M
$124.5M
Total DebtLower is stronger
$254.6M
Stockholders' EquityBook value
$568.4M
$949.8M
Total Assets
$1.6B
$1.5B
Debt / EquityLower = less leverage
0.27×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
ARWR
ARWR
KAI
KAI
Q4 25
$715.0M
Q3 25
$124.5M
Q2 25
$95.3M
Q1 25
$91.7M
Q4 24
$94.7M
Q3 24
$88.4M
Q2 24
$73.8M
Q1 24
$81.4M
Total Debt
ARWR
ARWR
KAI
KAI
Q4 25
Q3 25
$254.6M
Q2 25
$245.7M
Q1 25
$273.5M
Q4 24
$285.2M
Q3 24
$323.2M
Q2 24
$342.0M
Q1 24
$306.8M
Stockholders' Equity
ARWR
ARWR
KAI
KAI
Q4 25
$568.4M
Q3 25
$949.8M
Q2 25
$926.0M
Q1 25
$876.0M
Q4 24
$847.1M
Q3 24
$851.7M
Q2 24
$807.7M
Q1 24
$782.7M
Total Assets
ARWR
ARWR
KAI
KAI
Q4 25
$1.6B
Q3 25
$1.5B
Q2 25
$1.5B
Q1 25
$1.4B
Q4 24
$1.4B
Q3 24
$1.5B
Q2 24
$1.5B
Q1 24
$1.4B
Debt / Equity
ARWR
ARWR
KAI
KAI
Q4 25
Q3 25
0.27×
Q2 25
0.27×
Q1 25
0.31×
Q4 24
0.34×
Q3 24
0.38×
Q2 24
0.42×
Q1 24
0.39×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
ARWR
ARWR
KAI
KAI
Operating Cash FlowLast quarter
$13.5M
$47.3M
Free Cash FlowOCF − Capex
$11.3M
$44.1M
FCF MarginFCF / Revenue
4.3%
16.2%
Capex IntensityCapex / Revenue
0.8%
1.2%
Cash ConversionOCF / Net Profit
0.44×
1.70×
TTM Free Cash FlowTrailing 4 quarters
$145.9M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
ARWR
ARWR
KAI
KAI
Q4 25
$13.5M
Q3 25
$47.3M
Q2 25
$40.5M
Q1 25
$22.8M
Q4 24
$51.9M
Q3 24
$52.5M
Q2 24
$28.1M
Q1 24
$22.8M
Free Cash Flow
ARWR
ARWR
KAI
KAI
Q4 25
$11.3M
Q3 25
$44.1M
Q2 25
$36.5M
Q1 25
$19.0M
Q4 24
$46.3M
Q3 24
$48.3M
Q2 24
$23.1M
Q1 24
$16.6M
FCF Margin
ARWR
ARWR
KAI
KAI
Q4 25
4.3%
Q3 25
16.2%
Q2 25
14.3%
Q1 25
7.9%
Q4 24
17.9%
Q3 24
17.8%
Q2 24
8.4%
Q1 24
6.7%
Capex Intensity
ARWR
ARWR
KAI
KAI
Q4 25
0.8%
Q3 25
1.2%
Q2 25
1.6%
Q1 25
1.6%
Q4 24
2.2%
Q3 24
1.5%
Q2 24
1.8%
Q1 24
2.5%
Cash Conversion
ARWR
ARWR
KAI
KAI
Q4 25
0.44×
Q3 25
1.70×
Q2 25
1.55×
Q1 25
0.95×
Q4 24
2.16×
Q3 24
1.66×
Q2 24
0.90×
Q1 24
0.92×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

ARWR
ARWR

Segment breakdown not available.

KAI
KAI

Flow Control$94.8M35%
Capital$83.2M31%
Material Handling Systems$70.3M26%
Transferred Over Time$17.1M6%
Other$6.1M2%

Related Comparisons